EPHA2 and prostate carcinoma: Doxazosin successfully inhibited AKT and ERK kinase activities in an EphA2-dependent manner, triggered EphA2 receptor internalization, suppressed migration of prostate, breast, and glioma cancer cells, reduced distal metastasis of human prostate cancer cells, and prolonged survival in mice [76].